Tiburon Subsea & Ocean Floor Geophysics Sign MOU to Expand Capabilities of Revolutionary AUV Design
NEW YORK, Jan. 27, 2025 /PRNewswire/ -- Tiburon Subsea Inc. (TSI) and Ocean Floor Geophysics Inc. (OFG) are excited to announce their professional collaboration for 2025.
In 2024, Tiburon Subsea introduced its patented vectored thrust control system JETTE for defense markets and established AUV manufacturers.
In 2025, Tiburon is launching an initiative to develop its own revolutionary commercial AUV with its patent-pending technology. As a key part of this initiative, Tiburon announces an agreement to incorporate OFG's Self-Compensating Magnetometer, Hypermag, iCP, and HyperEMF systems for non-contact cathodic protection inspection, AC/DC cable EMF and depth of burial, and UXO survey.
"Our respective companies share a goal and vision of creating new subsea survey and inspection capabilities for our clients. We believe that advancing dynamic underwater technologies will propel us into a new era in marine robotics. Consider how satellite networks are the backbone hardware of the earth's science data network; autonomous vehicles are quickly becoming the same backbone needed to open data acquisition on a planet which is 70% water. Renewable energy, climate change remediation, marine fishery protection, weather monitoring, and coastal engineering will all benefit from access to this technology," writes Tiburon Subsea Founder and CEO, Tim Taylor.
TSI's revolutionary design offers hydrodynamic efficiency and redundancy and allows autonomous underwater vehicles to operate in all dimensions. Essentially, Tiburon Subsea is offering a dual market product. The JETTE system can provide all AUV manufacturers with vehicles featuring the ability to traverse any environment, hover, scan, stabilize, and carry larger payloads with more power. This new technology solves multiple shortcomings of current vehicles.
Ideal uses for the Tiburon fleet will include site exploration, oceanographic research, biodiversity management, defense, wind and wave renewable energy survey and maintenance, export and inter-array cable inspection, hydrographic survey, subsea security, methane leak detection, and coastal health monitoring. Tiburon Subsea is expanding into a platform that will disrupt current industry processes and help its clients overcome barriers to technology.
OFG CEO Matthew Kowalczyk states: "I have worked with Tim Taylor on many subsea projects throughout the years and his latest tech innovation will allow us to deploy our systems on a platform with unique capabilities to provide comprehensive data to our clients and the underwater marine community. OFG and Tiburon Subsea share a belief that the future of the ocean economy is digital, autonomous, and resident. That future requires quality data."
About OFG OFG provides solutions to address our clients' subsea surveying challenges across a range of markets including the renewables, oil and gas, defense and minerals sectors. OFG brings together expert teams of engineers and geoscientists to design, integrate and operationalize complex sensor systems deployed from AUV, ROV, USV and surface vessels. OFG collects rich multiphysics datasets and interprets these to meet and exceed survey objectives efficiently and safely, with minimal environmental impact. More info on OFG can be found at www.oceanfloorgeophysics.com.
About Tiburon Subsea Founded by acclaimed ocean explorer Tim Taylor and famed ocean scientist Dr. Sylvia Earle, Tiburon Subsea is building the world's first global autonomous undersea drone and data technology platform. TSI's new commercial AUV will be equipped with the proprietary JETTE thruster system, offering more speed, maneuverability, reliability, and versatility than current defense industry and commercial survey vehicles. Companies interested in access to survey quality AUV systems are encouraged to learn more at www.tiburonsubsea.com.
For more information contact Christine Dennison - Media Relations: 389205@email4pr.com or 917-423-1369.
View original content to download multimedia:https://www.prnewswire.com/news-releases/tiburon-subsea--ocean-floor-geophysics-sign-mou-to-expand-capabilities-of-revolutionary-auv-design-302359867.html
SOURCE Tiburon Subsea, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 days ago
- Business Wire
Latest Data of InnoCare's Robust Oncology Pipelines Presented at the 2025 ASCO Annual Meeting
BEIJING--(BUSINESS WIRE)--Latest data of InnoCare's robust oncology pipelines were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, involving the anti-CCR8 antibody ICP-B05 (CM369), the BCL2 inhibitor mesutoclax (ICP-248) and the pan-TRK inhibitor zurletrectinib (ICP-723). Latest data of InnoCare's robust oncology pipelines were presented at the 2025 ASCO Annual Meeting, involving the anti-CCR8 antibody ICP-B05 (CM369), the BCL2 inhibitor mesutoclax (ICP-248) and the pan-TRK inhibitor zurletrectinib (ICP-723). Oral Presentation Title: Preliminary results from the dose-escalation stage of a phase I trial of an anti-CCR8 antibody in patients with relapsed/refractory cutaneous T-cell lymphoma (R/R CTCL) (Abstract No.: 2514) The current study is the first and only report on the preliminary efficacy data of anti-CCR8 targeted therapy for CTCL patients. The efficacy of ICP-B05 was supported by the PD effects in both skin lesions and peripheral blood in the depletion of CCR8+ cells. ICP-B05 is safe and well tolerated and its safety profile made it a good candidate for combo therapies for CTCL patients with lymph node and other organ involvement. As of Jan. 6, 2025, a total of 13 patients with R/R CTCL were treated. There were 12 patients received at least one skin lesion assessment followed the mSWAT. 33.3% of patients achieved PR, and 58.3% of patients were assessed as SD with reduction in skin lesion. The 6-month PFS rate was 82.5%, and the median PFS was 11.4 months. Among the five patients with CCR8+ levels exceeding 10%, four (80%) achieved PR. PK analysis showed that serum exposure (Cmax and AUC0-14D) increased with dose escalation. PD analysis demonstrated significant depletion of CCR8-expressing cells in CTCL skin lesions. Poster 1: Title: Preliminary safety and efficacy data of ICP-248, a novel BCL2 inhibitor, in patients with relapsed or refractory B-cell malignancies (Abstract No.: 7038) The results of ICP-248 monotherapy suggests a well-tolerated safety profile and an exciting efficacy in BTK failed, heavily treated, relapsed or refractory B-cell malignancies. As of April 15, 2025, a total of 68 patients were enrolled in the dose escalation and dose expansion study. 17 R/R CLL/SLL and 32 R/R MCL patients were treated with 125 mg of ICP-248, including 10 CLL/SLL and 25 MCL patients were previously treated with BTK inhibitors, and 70.0% of CLL/SLL patients and 100% of MCL patients were resistant to BTK inhibitors. 17 CLL/SLL and 26 MCL patients had at least one response assessment. Among the BTK naïve patients, the ORR for R/R CLL/SLL and R/R MCL patients were both 100%, and the CRR was 14.3% and 71.4% respectively, of which 43% of MCL patients reported undetectable minimal residual disease (uMRD). Among the BTK treated patients, the ORR for R/R CLL/SLL and R/R MCL patients were 100% and 78.9% respectively, and the CRR were 30.0% and 26.3% respectively, of which uMRD was reported in 20% of CLL/SLL and 16% of MCL patients. The median PFS of R/R MCL patients who had received treatment of BTK inhibitors before was 8.3 months. The PFS was not reached among BTK naïve R/R CLL/SLL and R/R MCL patients and BTK-treated R/R CLL/SLL patients. Poster 2: Title: Efficacy, safety and pharmacokinetics (PK) of zurletrectinib, a next-generation pan-TRK inhibitor, in pediatric and adolescent patients with NTRK fusion-positive (NTRK+) solid tumors (Abstract No.: 10048) The integrated analysis demonstrated that zurletrectinib had significant efficacy and good safety profile in pediatric and adolescent patients with NTRK+ solid tumors. Zurletrectinib also showed the potential to overcome the resistance to first generation TRK inhibitors. These findings support zurletrectinib is a better treatment option for NTRK+ pediatric and adolescent patients. As of Nov. 23, 2024, 18 patients in total were enrolled, including 8 pediatric patients and 10 adolescent patients. Among the 18 patients, 6 TRK inhibitor treatment-naïve patients with central lab confirmed NTRK+ were efficacy evaluable. The confirmed ORR assessed by IRC was 100%. All patients achieved partial response (PR) at the first tumor assessment and maintained the remission as of the cutoff date. Median time to response were 1.0 month in adolescent patients and 0.9 month in pediatric patients. It is worth noting that one pediatric patient who progressed on prior first-generation TRK inhibitor achieved complete response after receiving zurletrectinib. Poster 3: Title: Updated efficacy and safety of zurlectrectinib in adult patients (pts) with locally advanced or metastatic NTRK fusion-positive (NTRK+) solid tumors (Abstract No.: 3112) In line with previously reported results, zurletrectinib continued to demonstrate a deep and durable responses in adult patients with NTRK+ advanced solid tumors with or without brain metastasis. Zurletrectinib was also well-tolerated and showed favorable safety profile in adult patients with various tumor types. As of Nov. 23, 2024, a total of 49 TRK inhibitor naïve adult patients were evaluable for efficacy representing 12 different solid tumor types. Among the efficacy population, the distribution of NTRK1, NTRK2 and NTRK3 fusions was 53.1%, 2.0% and 44.9% respectively. The confirmed ORR by IRC was 83.7%, with CR of 10.2%. Median duration of response (DOR) and median progression-free survival (PFS) by IRC were not reached. The DOR rate and PFS rate by IRC at 12 months was 92.0% and 90.5% respectively. Two of the three patients who had brain metastasis at the baseline achieved intracerebral ORR, which is consistent with the good brain penetration and strong intracranial activity of zurletrectinib. The 2025 ASCO Annual Meeting is held from May 30 to June 3, 2025 in Chicago, U.S. The ASCO annual meeting is the most important and professional academic event in the global oncology field, which showcases the international cutting-edge clinical oncology research results and tumor treatment technologies. About InnoCare InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancers and autoimmune diseases with unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States. InnoCare Forward-looking Statements This report contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management's intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance.
Yahoo
5 days ago
- Yahoo
NASA spots sputtering for first time, cracks Mars' lost atmosphere mystery
Mars just gave up one of its oldest secrets — and it took a decade, a spacecraft, and a cosmic cannonball to catch it in the act. For the first time, NASA's MAVEN mission has directly observed a process called sputtering, an elusive atmospheric escape mechanism where energetic charged particles from the solar wind slam into the Martian atmosphere, knocking atoms into space. This violent interaction may be a key reason why Mars lost its thick atmosphere and, with it, the ability to sustain liquid water on its surface. The breakthrough marks a major milestone for MAVEN, a mission under NASA's Mars Exploration Program dedicated to uncovering how the Red Planet lost its atmosphere. While scientists had long suspected the process played a role in the Red Planet's atmospheric erosion, they lacked concrete evidence. 'It's like doing a cannonball in a pool,' said Shannon Curry, principal investigator of MAVEN at the Laboratory for Atmospheric and Space Physics at the University of Colorado Boulder and lead author of the study in a release. 'The cannonball, in this case, is the heavy ions crashing into the atmosphere really fast and splashing neutral atoms and molecules out.' Previous findings—like the imbalance between lighter and heavier argon isotopes in Mars' atmosphere—offered only indirect clues, pointing to sputtering's fingerprints without capturing the act itself. Since lighter isotopes naturally reside higher in the atmosphere, their scarcity compared to heavier ones strongly suggested they had been knocked away into space. And the only known process capable of selectively removing these lighter isotopes is sputtering. 'It is like we found the ashes from a campfire,' said Curry. 'But we wanted to see the actual fire, in this case sputtering, directly.' Now, using data from three instruments aboard MAVEN—the Solar Wind Ion Analyzer, the Magnetometer, and the Neutral Gas and Ion Mass Spectrometer—researchers have, for the first time, captured sputtering in action. Additionally, the team needed measurements across the dayside and the nightside of the planet at low altitudes, which takes years to observe. By combining data from three of MAVEN's instruments, scientists created the first detailed map linking sputtered argon to incoming solar wind. The map showed argon atoms high in the Martian atmosphere, precisely where energetic particles had slammed into it—clear, real-time evidence of sputtering in action. Even more striking, the process was occurring at a rate four times higher than expected, with activity intensifying during solar storms. This direct observation confirms that sputtering was a major driver of atmospheric loss during Mars' early years, when the young Sun was far more active. 'These results establish sputtering's role in the loss of Mars' atmosphere and in determining the history of water on Mars,' said Curry. The discovery helps fill a major gap in our understanding of Mars' transformation from a once-habitable planet to the cold, dry world we see today. It also provides critical insight into how planets evolve and what it might take for them to remain habitable. The findings have been published this week in Science Advances.
Associated Press
20-05-2025
- Associated Press
ORIGYN Acquires ClaimLink, Ushering in a New Era of Frictionless Tokenized Asset Distribution
NEUCHâTEL, SWITZERLAND, May 20, 2025 / / -- ORIGYN, the decentralized protocol for real-world asset (RWA) certification, announced the acquisition of ClaimLink, an on-chain NFT and token distribution platform natively built on the Internet Computer (ICP) blockchain. The acquisition strengthens ORIGYN's mission to deliver accessible, user-friendly web3 infrastructure for certifying and distributing tokenized assets fully on-chain. ClaimLink is helping creators and communities distribute assets effortlessly and securely through a user experience that mirrors Web2 simplicity while maintaining Web3 ownership principles. With its integration, ORIGYN is uniquely positioned to onboard both crypto-native users and newcomers with ease. As the ORIGYN ecosystem continues to expand, with certificates for luxury goods, fine art, gold, diamonds and more, the ability to distribute tokenized assets frictionlessly becomes critical. By leveraging ClaimLink's capabilities into its growing ecosystem, ORIGYN will provide partners, creators, and enterprises with tools to easily manage certificates through decentralized claimable links, QR codes, and bulk dispensers. Key features of ClaimLink include: Seamless claiming of certificates via fully on-chain QR codes and links Easy integrations for partners distributing ORIGYN-certified assets Broadening of certificate distribution for physical locations and events Easier set-up for community rewards, campaigns, loyalty drops, and more 'ClaimLink is a natural fit for ORIGYN's ecosystem,' said the ORIGYN team in a statement. 'Its technology complements the protocol's vision of verifiable, decentralized ownership and lowers the barriers to engaging with tokenized assets. Together, we're making real-world asset certification and distribution more accessible and scalable than ever before.' Denis Stepanov, founder of ClaimLink, added: 'ClaimLink is entering a new chapter with the ORIGYN team continuing its development. Their expertise will help expand the platform's reach and impact within the ecosystem. I'm excited to see its growth and the value it will bring to the community.' ClaimLink will continue to operate within the ORIGYN ecosystem and remain open for builders, brands, and creators seeking to distribute digital assets without friction. To learn more about ClaimLink, visit and For additional information about ORIGYN, visit Tom Fraczak ORIGYN Foundation [email protected] Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
